Craft

Cassava Sciences

Stock Price

$22

2024-05-03

Market Capitalization

$953.6 M

2024-05-03

Cassava Sciences Summary

Company Summary

Overview
Cassava Sciences (formerly known as Pain Therapeutics) is a biopharmaceutical company that specializes in neuroscience. It offers Simufilam (formerly known as PTI-125), a drug that treats Alzheimer's disease; SavaDx (formerly known as PTI-125Dx) a blood-based diagnostic to detect Alzheimer's disease.
Type
Public
Status
Active
Founded
1998
HQ
Austin, TX, US | view all locations
Website
https://www.cassavasciences.com
Cybersecurity rating
ESG rating
40-49 out of 100|View all ESG data
Sectors

Key People

  • Remi Barbier

    Remi Barbier, Chairman of the Board, President & CEO

    • Nadav Friedmann

      Nadav Friedmann, Chief Medical Officer and Director

    • Richard J. Barry

      Richard J. Barry, Independent Director

      • Eric Schoen

        Eric Schoen, Chief Financial Officer

      LocationsView all

      1 location detected

      • Austin, TX HQ

        United States

        6801 N. Capital of Texas Highway, Building 1

      Cassava Sciences Financials

      Summary Financials

      Net income (FY, 2023)
      ($97.2M)
      Cash (FY, 2023)
      $121.1M
      EBIT (FY, 2023)
      ($106.0M)

      Footer menu